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348 0.43 (0.18 -1.06) 5,828 0.63 (0.47-0.86)
1-year
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348 0.74 (0.50 -1.09) 1,531 0.67 (0.51-0.88)
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348 4.77 (1.97–11.56) 2,182 2.77 (1.93–3.99)
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Background: Haemodynamic instability (HI) represent the most important intra-oper-
ative manifestation of major complications occurring during TAVI. The aim of this study
was to investigate the causes, risk factors and clinical signiﬁcance of HI during TAVI.
Methods: FromNovember 2007 to September 2013 all patients consecutively treated in
our center were included. HIwas deﬁned as a drop of mean arterial pressure 20mmHg
with a heart rate  100 or  50 beats/min for  1 min. Causes of HI were classiﬁed in
those occuring post-preparatory balloon aortic valvuloplasty (PBAV) and post-valve
implantation (VI). Each group was compared with a control group where HI did not
occur. Outcomes were assessed according to VARC 2 criteria at 30 days, 1 and 2 years.
Results: Overall, of 538 patients that underwent TAVI, 35 (7.4%) developed HI. Of
these 18/453 (3.9%) developed HI after PBAV, while 19/538 (3.5%) developed HI
after VI. Causes of HI after PBAV included severe aortic regurgitation (AR; n ¼ 12/
18; 66.6%), new-onset tachy- or brady-arrhythmia (n ¼ 4/18; 22.2%), aortic annulus
rupture (n ¼ 1/18; 5.5%) and cardiac tamponade (n ¼ 1/18; 5.5%). Causes of HI after
VI included aortic dissection (n ¼ 2/19; 10.5%), cardiac tamponade (n ¼ 14/19;
73.6%), coronary obstruction (n ¼ 2/19; 10.5%) and severe AR (n ¼ 1/19; 5.2%).
Patients that developed HI after PBAV had greater all-cause and cardiovascular
mortality at 30 days (respectively, 11.1% vs. 3%, p ¼ 0.023; and 11.1% vs. 1.8%, p ¼
0.009) while no differences were found in all-cause and cardiovascular mortality at 2
years of follow-up. Conversely patients that developed HI after implantation had
higher rates of all-cause and cardiovascular mortality at 30 days (respectively, 26.3%
vs. 2.7%, p < 0.001; and 21.1% vs. 1.9%, p < 0.001) and at 2-year follow-up
(respectively, 36.8% vs. 16.9%, p ¼ 0.025; and 26.3% vs. 9.3%; p ¼ 0.015).
Conclusions: HI can occur both after PBAV and VI. The most common cause of HI
after PBAV were severe AR. Conversely, the most common after VI was cardiac
tamponade. HI after PBAV was associated with a higher 30-day mortality but did not
affected long-term survival.
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Background: Vascular complications (VC) during transcatheter aortic valve im-
plantation (TAVI) are reported using various criteria and several access site ap-
proaches. We aimed to describe the prevalence of VC associated with TAVI via a
solely percutaneous trans-femoral approach and their predictive value for survival,
using both the updated Valve Academic Research Consortium-2 (VARC-2) criteria
and the former VARC-1 criteria.
Methods: Between March 2009 and September 2013, 403 consecutive patients at a
mean age (SD) of 836 underwent percutaneous trans-femoral TAVI. All pro-
cedures were performed using an 18/19 Fr. sheath. Vascular complications were
deﬁned by both VARC-1 and VARC-2 criteria and analyzed separately.
Results: VARC-1 and VARC-2 deﬁned VC occurred in 71 (18%) and 78 (19%)
patients, respectively, with 15 (4%) and 33 (8%) deﬁned as major VC. The difference
in frequency of major and minor VC was mainly driven by VARC-2 implementation
of major bleeding events. With either VARC deﬁnition, patients with minor VC had
similar mortality and complications rates as those patients without VC. In multivariate
analyses, referenced to patients with minor or no VC, only VARC-1 deﬁned major VC
were signiﬁcantly associated with increased mortality (HR 3.52; CI 1.5-8.4; p¼0.005),
whereas VARC-2 deﬁned major VC were found to be only marginally signiﬁcant (HR
1.9; CI 0.9-3.9; p¼0.08).
Conclusions: The VARC-2 VC criteria increase the observed rate of major VC
following TAVI mainly by the inclusion of major bleeding events, and by doing so
decrease their predictive usefulness on patient outcomes.
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Background: The Placement of Aortic Transcatheter Valves (PARTNER) study was
the ﬁrst randomized controlled study involving the Edwards SAPIEN valve. We
intended to compare outcomes of transfemoral(TF) vs transapical(TA) access for
Transcutaneous Aortic Valve Replacement (TAVR) between the rigorous PARTNER
trial environment and real-world patient registries.
Methods: We searched databases for Edwards SAPIEN TAVR studies comparing the
TF and TA approaches regarding the following outcomes: 30-day and 1-year mor-
tality; 30-day stroke; 30-day permanent pacemaker implantation; and 30-day vascular
complications. The outcomes were then compared between the PARTNER trial and
the pooled data from remaining studies.
Results: The PARTNER trial had 244 TF and 104 TA patients. In the pooled data
from 17 studies, TA patients had a signiﬁcantly higher EuroSCORE as compared to
TF patients (24.612.9 vs 21.312.0; p< 0.001). In the intention-to-treat analysis of
the PARTNER study the EuroSCORE was not signiﬁcantly different between the TA
and TF groups (29.815.9 vs 29.1 16.1; p¼0.61). As shown in Table 1, 30-day and
1-year mortality were similar between the two approaches in the PARTNER trial;
conversely, pooled results showed a signiﬁcantly decreased risk with the TF approach.
The PARTNER trial and remaining studies showed an increased incidence of 30-day
vascular complications in the TF arm and a similar risk of 30-day stroke incidence and
new pacemaker insertion between accesses.Conclusions: The observed difference in mortality is likely secondary to the effect of
randomization in thePARTNER trialwith comparable pre-proceduremortality risk scores
between the TA and TF arms. A reduction in the relative risk of vascular complications in
the TF arm in the pooled data vs PARTNER trial is likely due to improvement in overall
screening, valves with smaller delivery sheath, and increasing operator expertise.
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Background: In patients with aortic stenosis (AS), mitral regurgitation (MR) is a
common ﬁnding. While surgical treatment of AS has been shown to result in a
decrease in MR severity, little is known regarding outcomes in patients undergoing
transcatheter aortic valve implantation (TAVI). We aimed to characterize the short-
and mid-term impact of the procedure on MR grade.
Methods: We studied our TAVI patients and assessed the severity of MR at baseline,
1 month and 6 months after the procedure. Trans thoracic echocardiographic studies
were performed using a Philips IE33 by an experienced sonographer and reviewed by
a cardiologist specializing in echocardiography.
Results: 261 patients were included in the analysis(mean age 82.16.9 years, 59%
female). 74 patients (28.4%) had mild to moderate MR or above at baseline. In this
group, there was a mean reduction of 0.90.97 in the degree of regurgitation after 1
month and 1.21.1 after six months (p< 0.01). In patients with moderate MR or
above (n¼26, 10% of the cohort), the respective improvement rates were 1.51.1 and
1.81.4 (p< 0.01). Improvement of MR (1+ or greater) at six months was identiﬁed in
40/74 (54.1%) of patients with mild-moderate MR or above, and in 23/26 (88.5%) of
those with moderate MR or above, and was associated with improved functional class
(correlation coefﬁcient -0.294, p< 0.001).lvular disease - Aortic: TAVR B227
